Literature DB >> 9213354

Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells.

K Hupe-Sodmann1, R Göke, B Göke, H H Thole, B Zimmermann, K Voigt, G P McGregor.   

Abstract

This study concerns whether the pancreatic beta cell expresses cell-surface ectopeptidases that are capable of proteolysis of peptide hormones and neuropeptides that modify glucose-dependent insulin release. These biochemical investigations of the RINm5F cell line found that these cells express ectopeptidases. We have characterized the limited endoproteolysis of GLP-1 (7-36) amide that occurs in the presence of RINm5F plasma membranes. The products and the sensitivity to specific peptidase inhibitors of the proteolysis is characteristic of neutral endopeptidase (NEP) 24.11. Vasoactive intestinal polypeptide (VIP), pituitary adenylate cyclase-activating peptide (PACAP), amylin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), and exendin-4 also undergo proteolysis in the presence of RIN cell membranes. NEP 24.11-activity in RIN cell membranes was confirmed using a specific fluorogenic assay, by histochemistry, and by comparison with the recombinant enzyme with respect to the kinetics of proteolysis of GLP-1 (7-36) amide and of a fluorogenic substrate. Specific fluorogenic assays revealed the presence of aminopeptidase N and the absence of aminopeptidase A and of dipeptidylpeptidase IV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9213354     DOI: 10.1016/s0196-9781(97)00123-x

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  15 in total

1.  Glucagon increase after chronic AT1 blockade is more likely related to an indirect leptin-dependent than to a pancreatic α-cell-dependent mechanism.

Authors:  Martin Mildner; Helge Müller-Fielitz; Ines Stölting; Olaf Jöhren; Muscha Steckelings; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-31       Impact factor: 3.000

2.  Why is it so difficult to measure glucagon-like peptide-1 in a mouse?

Authors:  Johanne A Windeløv; Nicolai J Wewer Albrechtsen; Rune E Kuhre; Sara L Jepsen; Daniel Hornburg; Jens Pedersen; Elisa P Jensen; Katrine D Galsgaard; Marie Winther-Sørensen; Anne Ørgaard; Carolyn F Deacon; Matthias Mann; Hannelouise Kissow; Bolette Hartmann; Jens J Holst
Journal:  Diabetologia       Date:  2017-07-01       Impact factor: 10.122

3.  GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity.

Authors:  Zhengu Liu; Violeta Stanojevic; Luke J Brindamour; Joel F Habener
Journal:  J Endocrinol       Date:  2012-03-13       Impact factor: 4.286

4.  Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.

Authors:  Joshua R Willard; Breanne M Barrow; Sakeneh Zraika
Journal:  Diabetologia       Date:  2016-12-08       Impact factor: 10.122

5.  Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.

Authors:  A Plamboeck; J J Holst; R D Carr; C F Deacon
Journal:  Diabetologia       Date:  2005-07-16       Impact factor: 10.122

6.  Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with β-cell dysfunction.

Authors:  Nathalie Esser; Stephen M Mongovin; Jacqueline Parilla; Breanne M Barrow; Thomas O Mundinger; Brendy S Fountaine; Megan J Larmore; Joseph J Castillo; Rehana Akter; Rebecca L Hull; Sakeneh Zraika
Journal:  Am J Physiol Endocrinol Metab       Date:  2022-02-07       Impact factor: 4.310

7.  Neprilysin Deficiency Is Associated With Expansion of Islet β-Cell Mass in High Fat-Fed Mice.

Authors:  Jacqueline H Parilla; Rebecca L Hull; Sakeneh Zraika
Journal:  J Histochem Cytochem       Date:  2018-03-19       Impact factor: 2.479

Review 8.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

Review 9.  Unraveling oxyntomodulin, GLP1's enigmatic brother.

Authors:  Alessandro Pocai
Journal:  J Endocrinol       Date:  2012-09-27       Impact factor: 4.286

Review 10.  Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions.

Authors:  Awadhesh Kumar Singh
Journal:  Indian J Endocrinol Metab       Date:  2014-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.